Not reported in abstract.
Immune & thymic support sketch
Protocol overview
Immune-modulation oriented protocol sketch around Thymosin Alpha-1, Sermorelin, and NAD+.
Protocol details
Loose grouping of immune and repair-adjacent agents.
- Focus: immune modulation, thymic support, and cellular energy
- Core agents: Thymosin Alpha-1, Sermorelin, NAD+
- Note: regulatory context and indication-specific approvals differ widely by region.
Linked peptides
Peptides that appear in this protocol, with their primary perceived effect profiles.
Thymosin Alpha-1Peptide
### Thymosin Alpha-1 Summary Thymosin Alpha-1 (Tα1) is a peptide that plays a crucial role in modulating immune responses and has been investigated for its potential therapeutic applications in various conditions, including infections and inflammatory diseases.
SermorelinPeptide
### Summary Sermorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to produce and release endogenous growth hormone. It has been investigated for its potential therapeutic applications, particularly in the context of growth hormone deficiencies and other related conditions.
NAD+Peptide
### Summary NAD+ (Nicotinamide adenine dinucleotide) is a crucial coenzyme involved in various metabolic processes, including energy production and cellular repair mechanisms. Recent research highlights its potential roles in protecting against oxidative stress and enhancing therapeutic efficacy in certain cancer treatments.
Community tags (where this is used)
Lightweight, anonymous voting on where this protocol tends to show up in people's research (not recommendations or medical guidance).
Community stacks, dosing & cycles
Anonymous, research-framed suggestions for how people structure this protocol in practice. No medical advice; use as inspiration, then cross-check against primary evidence.
No community variants logged yet. The sample row below is illustrative until real submissions appear.
| Variant | Stack | Dosage | Cycle | Submitted | Upvotes |
|---|---|---|---|---|---|
Sample: 8-week tendon stack (example) Illustrative structure only. Replace with real-world, research-framed variants once community submissions are available. | BPC-157 + TB-500 + progressive PT 3x/week; sleep and protein focus | e.g. BPC-157 ~250 mcg daily, TB-500 twice weekly | 8–12 weeks, then reassess / deload | — | — |
Not reported in abstract.
Not reported in abstract.
Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.PubMedSermorelin
This study investigates the effects of growth hormone-releasing hormone antagonists on radiosensitivity in non-small cell lung cancer cells. The specific doses and methodologies used are not detailed in the abstract. The findings suggest a potential increase in radiosensitivity, but further details are required for a comprehensive understanding.
This study investigates the effects of growth hormone-releasing hormone antagonists on autophagy in cancer cells. The specific measurements, doses, and populations involved are not detailed in the abstract. The findings may have implications for understanding cancer cell biology.
Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.PubMedThymosin Alpha-1
This systematic review and meta-analysis evaluated the efficacy of thymosin α1 in patients with sepsis. The study synthesized data from randomized controlled trials to assess the impact of thymosin α1 on clinical outcomes. Not reported in abstract.
Thymosin α1 Combined With 2HRZE/4HR Regimen as a Potential Treatment of Pulmonary Tuberculosis: An Analysis of Immune Function, Pulmonary Function and Inflammatory Response.PubMedThymosin Alpha-1
This study evaluated the effects of Thymosin Alpha-1 combined with a 2HRZE/4HR regimen on immune function, pulmonary function, and inflammatory response in patients with pulmonary tuberculosis. The specific doses and outcomes were not detailed in the abstract. The findings suggest potential interactions between Thymosin Alpha-1 and tuberculosis treatment, but no therapeutic claims are made.
Thymosin α1 alleviates pulpitis by inhibiting ferroptosis of dental pulp cells.PubMedThymosin Alpha-1
This study investigates the effects of Thymosin Alpha-1 on pulpitis by examining its role in inhibiting ferroptosis in dental pulp cells. The specific dosage and duration of treatment were not reported in the abstract. The findings suggest a potential mechanism by which Thymosin Alpha-1 may alleviate pulpitis.
Single-cell analysis integrated with RNA-Sequencing uncovers new action of Patchoulol on adipose tissue remodeling in obesity.PubMedNAD+
This study investigates the effects of Patchoulol on adipose tissue remodeling in obesity using single-cell analysis integrated with RNA-Sequencing. The specific doses and population details are not reported in the abstract. The findings suggest new actions of Patchoulol in the context of obesity-related adipose tissue changes.
Nicotinamide riboside enhances the efficacy of gemcitabine and suppresses PDAC premalignant lesions via SIRT3 activation.PubMedNAD+
This study investigates the effects of nicotinamide riboside on the efficacy of gemcitabine and the suppression of pancreatic ductal adenocarcinoma (PDAC) premalignant lesions. The study appears to focus on SIRT3 activation as a mechanism of action. Not reported in abstract.
SMP30 May protect human lens epithelial cells against high glucose-induced oxidative damage by regulating the Keap1/Nrf2/NQO1 pathway.PubMedNAD+
This study investigates the protective effects of SMP30 on human lens epithelial cells exposed to high glucose levels. The focus is on the regulation of the Keap1/Nrf2/NQO1 pathway. No specific dose or quantitative outcomes are reported in the abstract.